A brain inflammation marker has been identified in patients at early asymptomatic stages of Alzheimer's disease. This secreted marker molecule, which can be measured from cerebrospinal fluid taps, may provide clinicians with a rapidly detectable biomarker for the transition from preclinical Alzheimer's disease to cognitive impairment and progression to full dementia. Such is the conclusion of a multi-center study on a large group of human patients.

Source: New biomarker of brain inflammation in early-stage Alzheimer's disease


David Cottle

UBB Owner & Administrator